ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Hepatocyte PIEZO1 Negatively Regulates Lipogenesis and Ameliorates MASLD by Sensing Membrane Tension and Activating AMPK.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Liver is a central organ for lipid metabolism. Disruption of lipid homeostasis leads to lipid accumulation in hepatocytes, which is a feature of metabolic dysfunction-associated steatotic liver disease (MASLD). Mechanical force and mechanosensitive proteins have been found to play a crucial role in energy metabolism. However, their role in hepatic lipid metabolism remains unclear. In this study, mechanosensitive ion channel PIEZO1 is detected in hepatocytes, and downregulated in the liver of MASLD patients and high-fat diet (HFD)-induced MASLD mouse model. Under HFD feeding, mice with hepatocyte-specific Piezo1 deletion exhibit severer triglyceride accumulation, upregulation of de novo lipogenesis genes, and decreased phosphorylation of AMPK and RAPTOR in the liver. In contrast, injection of PIEZO1 activator Yoda1 alleviates triglyceride accumulation, downregulates lipogenesis genes and enhances phosphorylation of AMPK and RAPTOR in HFD-fed C57BL/6 mice. Knockdown of PIEZO1 in HepG2 leads to upregulation of lipogenesis genes and impairs AMPK-RAPTOR pathway, while Yoda1 or hypotonic treatment do the reverse. The effects of PIEZO1 knockdown and Yoda1 treatment can be abolished by AMPK activator and CaMKK2/AMPK inhibitors, respectively. These findings suggest that PIEZO1 can respond to changes in membrane tension and activate AMPK, thereby inhibiting lipogenesis and maintaining lipid homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.